Blue Chip, an independent, full-service global marketing agency, announced the launch of Blue Chip Patient Recruitment (BCPR), a division dedicated to serving pharmaceutical and biotech clients with clinical trial recruitment marketing. BCPR's first client is BioSante Pharmaceuticals, Inc.
"We are pleased to launch the new division with an integrated program for BioSante," said Blue Chip Chairman and CEO Stanton Kawer. "Our track record to date has included conducting nearly 600 clinical trials with a 90 percent success rate, making the launch of Blue Chip Patient Recruitment a natural evolution of our business."
BCPR uses a scientific and tested approach to clinical trial marketing that combines proprietary predictive modeling tools with original patient acquisition strategies and continuous evaluation. It leverages Blue Chip's ability to develop the appropriate media and buying mix with firsthand experience in helping physicians effectively manage the site recruitment process to deliver maximum results.
BioSante Pharmaceuticals is an Illinois-based pharmaceutical company focused on developing products for female sexual health and oncology. BCPR is conducting a centrally-managed patient recruitment marketing program for its Phase 3 clinical trial called the Bloom Study. It investigates the safety and efficacy of LibiGel®, an investigational medication for the treatment of Hypoactive Sexual Desire Disorder (HSDD).
"Blue Chip Patient Recruitment is executing a comprehensive and creative marketing campaign, including a web-based solution that is critical to the success of the overall program," said Bill Milling, Senior Director of Operations, BioSante Pharmaceuticals.
At the outset, the Bloom Study presented several unique patient recruitment challenges: a very narrow patient population, multiple study protocols and a patient population difficult to reach through mass media. BCPR overcame these challenges by focusing on cost-effective, results-oriented strategies including a digital marketing component. The digital program incorporated behavioral and contextual retargeting strategies and tracking and analysis of thousands of pre-qualified leads.
In addition to BioSante Pharmaceuticals, Blue Chip has developed patient recruitment programs for Novartis, Johnson & Johnson, Pfizer, AstraZeneca, Abbott and Takeda, among others.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.